Tiziana Life Sciences is trading at $0.99, down 5.67%, amid recent financial disclosures that are a plausible source of pressure, though no report confirms they caused the October 19 decline. - October 16 interim results showed a $12.4 million first-half comprehensive loss, versus $5.3 million a year earlier. - Cash was $3.9 million as of October 16; total liabilities were $14.4 million. - The Alzheimer’s trial dosing milestone was announced October 16; it does not explain the current drop.